BCAX
HealthcareBicara Therapeutics Inc. Common Stock · Biotechnology · $1B
What is Bicara Therapeutics Inc. Common Stock?
Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies targeting solid tumors. Based in Boston, Massachusetts, it operates as a subsidiary of Biocon Limited and is working to advance a novel class of cancer treatments.
Bicara Therapeutics develops bifunctional antibody therapies designed to attack solid tumors through two simultaneous mechanisms. Its lead candidate, ficerafusp alfa, combines an EGFR-directed monoclonal antibody with a domain that targets TGF-beta — a signaling pathway that helps tumors evade the immune system. By blocking both pathways at once, the company aims to improve outcomes in cancers where single-agent approaches have shown limited efficacy. Revenue generation depends entirely on clinical and regulatory progress.
Bicara Therapeutics was incorporated in 2018 and is headquartered in Boston, Massachusetts.
- Ficerafusp alfa — lead bifunctional antibody for solid tumor treatment
- EGFR-targeting monoclonal antibody component
- TGF-beta inhibition domain for immune evasion blockade
- Clinical-stage oncology pipeline for solid tumors
Is BCAX a Good Stock to Buy?
UQS Score rates BCAX as Poor overall, reflecting the early-stage nature and inherent uncertainties of its clinical program.
The most constructive element in BCAX's profile is its Risk pillar, which scores Good — suggesting the company's balance sheet and near-term financial structure are relatively stable compared to many clinical-stage peers. This provides some runway for pipeline advancement without immediate liquidity pressure.
Quality, Moat, and Growth all register as Weak, which is typical for pre-revenue biotechs but signals meaningful uncertainty. Valuation is rated Elevated, meaning the market may already be pricing in optimistic clinical outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BCAX pay dividends?
No — Bicara Therapeutics Inc. Common Stock does not currently pay a dividend.
BCAX does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward research, clinical trials, and regulatory activities. Investors in BCAX are taking on development-stage risk in exchange for potential upside tied to pipeline milestones rather than income distributions.
When does BCAX report earnings?
Bicara Therapeutics reports financial results on a quarterly cadence, consistent with US-listed equities.
As a clinical-stage company, BCAX does not generate product revenue. Quarterly reports primarily reflect research and development expenditures, operating expenses, and cash position updates — all of which are key indicators of runway and pipeline progress.
For the most recent quarter's results and pipeline updates, visit Bicara Therapeutics' investor relations page directly.
BCAX Price History
-9.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Bicara Therapeutics Inc. Common Stock?
Based on Bicara Therapeutics Inc. Common Stock's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BCAX Long-term Outlook
The fundamental outlook for BCAX is shaped almost entirely by clinical trial outcomes for ficerafusp alfa. With Growth and Quality both rated Weak, near-term financial improvement is unlikely without a meaningful regulatory or partnership catalyst. The Good Risk rating suggests the company has structured its balance sheet to weather the development period, but the Elevated Valuation label indicates the market may have already priced in a degree of clinical success that has yet to materialize.
Growth drivers
- Advancement of ficerafusp alfa through clinical trial milestones
- Potential partnership or licensing deals leveraging Biocon Limited's backing
- Expanding clinical data in solid tumor indications with high unmet need
Key risks
- Clinical trial failure or disappointing efficacy data for ficerafusp alfa
- Elevated valuation leaves limited margin of safety if pipeline progress stalls
- Pre-revenue model means continued cash burn with no near-term revenue offset
BCAX vs Peers
BCAX operates in a competitive clinical-stage oncology space alongside several other development-focused biotechs.
MoonLake focuses on nanobody-based therapies targeting inflammatory diseases rather than oncology, representing a different therapeutic area and risk profile.
ArriVent targets EGFR-mutant lung cancer with small-molecule approaches, overlapping with BCAX's EGFR focus but using a distinct drug modality.
Inhibrx develops multispecific protein therapeutics across oncology and rare disease, sharing the bifunctional molecule design philosophy but with a broader pipeline scope.
Frequently Asked Questions
What does Bicara Therapeutics do?
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies for solid tumors. Its lead program, ficerafusp alfa, simultaneously targets EGFR and TGF-beta to block tumor growth and immune evasion. The company is a subsidiary of Biocon Limited and is based in Boston, Massachusetts.
Does BCAX pay dividends?
No, BCAX does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and development. Investors should not expect income distributions from BCAX in the near term.
When does BCAX report earnings?
Bicara Therapeutics reports on a quarterly cadence, as is standard for US-listed companies. Because it is pre-revenue, reports focus on pipeline progress and cash runway rather than sales figures. Check the company's investor relations page for the latest schedule.
Is BCAX a good stock to buy?
UQS Score rates BCAX as Poor overall. The Risk pillar is the strongest element, while Quality, Moat, and Growth are all Weak. Valuation is Elevated. This profile reflects the high uncertainty typical of clinical-stage biotechs. The full pillar breakdown is available to UQS Pro members.
Is BCAX overvalued?
The UQS Valuation pillar for BCAX is rated Elevated, suggesting the current market price may already reflect optimistic assumptions about clinical outcomes. For a pre-revenue company, valuation is inherently speculative and tied closely to pipeline milestones rather than current earnings.
How does BCAX compare to its competitors?
BCAX competes in the clinical-stage oncology space alongside companies like MoonLake Immunotherapeutics, ArriVent BioPharma, and Inhibrx Biosciences. Each pursues different modalities or indications, but all share the development-stage risk profile common to pre-revenue biotechs. UQS Pro members can view side-by-side pillar comparisons.
What is BCAX's market cap bracket?
BCAX is classified as a small-cap stock. This is typical for clinical-stage biopharmaceutical companies that have not yet generated product revenue and whose valuation is driven primarily by pipeline potential and clinical progress.
Who founded Bicara Therapeutics?
Bicara Therapeutics was incorporated in 2018. The company operates as a subsidiary of Biocon Limited, a major global biopharmaceutical group. For detailed founding history and leadership information, the company's official website and SEC filings are the most reliable sources.
Is BCAX a long-term quality investment?
As a long-term quality indicator, BCAX's current UQS profile — with Weak scores across Quality, Moat, and Growth — reflects the structural limitations of a pre-revenue clinical-stage company. Long-term quality typically improves as pipeline assets advance and revenue visibility increases. The full analysis is available to Pro members.
What is the main competitive advantage of Bicara Therapeutics?
Bicara's potential differentiation lies in its bifunctional antibody approach, which simultaneously targets two tumor-promoting pathways — EGFR and TGF-beta — in a single molecule. If clinical data supports this dual mechanism, it could offer an advantage over single-pathway therapies in certain solid tumor settings.
Is BCAX a growth stock or value stock?
Based on UQS pillar labels, BCAX carries a Weak Growth rating and an Elevated Valuation rating. This combination is characteristic of early-stage biotechs where investors are paying a premium for future potential rather than current financial performance. It does not fit the traditional profile of either a growth or value stock.
Unlock Full BCAX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare BCAX to peers on every quality dimension
- ✓Track pipeline-driven risk and valuation signals
- ✓Get the full analyst view available to Pro members
Pro Analysis
BCAX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | 11.9 | 0.0 | 13.0 | 0.0 | 57.4 | 0.0 | -1.8 |
| Apr 2, 2026 | 13.7 | 0.0 | 13.0 | 0.0 | 69.4 | 0.0 | — |
BCAX — Pillar Breakdown
Quality
— 0.0/100 (25%)Bicara Therapeutics Inc. Common Stock currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Bicara Therapeutics Inc. Common Stock faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 57.4/100 (15%)Bicara Therapeutics Inc. Common Stock maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Bicara Therapeutics Inc. Common Stock appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)Bicara Therapeutics Inc. Common Stock operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BCAX.
Score Composition
Financial Data
More Stock Analysis
How is the BCAX UQS Score Calculated?
The UQS (Unified Quality Score) for Bicara Therapeutics Inc. Common Stock is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Bicara Therapeutics Inc. Common Stock's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Bicara Therapeutics Inc. Common Stock is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.